This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (70)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John L. Keltner, MD; Charles E. Thirkill, PhD; Nancy K. Tyler, PhD; Alan M. Roth, MD

Arch Ophthalmol. 1992;110(1):48-53.

Abstract
• Cancer-associated retinopathy is a rare paraneoplastic event that can involve allergic reactions and result in retinal degradation. A patient, who had a 35-year smoking history, complained of visual loss and was found to have serum antibodies that reacted with an extract of retina, including the previously described retinal cancer-associated retinopathy antigen. Prednisone treatment appeared to reduce the patient's antibody titers to normal levels. Visual fields stabilized, and the patient was able to maintain useful vision throughout the course of treatment until his death 1 year following initial diagnosis. To our knowledge, this is the first reported case in which monitoring of antibody responses to retinal antigens appeared to be useful in the decision whether to initiate prednisone therapy. Rising antibody titers to the cancer-associated retinopathy antigen probably occurs before progressive visual field loss and may be considered an indication for prompt steroid therapy.

Author Affiliations
From the Departments of Ophthalmology (Drs Keltner, Thirkill, Tyler, and Roth), Neurology and Neurological Surgery (Dr Keltner), and Pathology (Dr Roth), University of California, Davis, Medical Center.

Footnotes
Accepted for publication September 4, 1991.

Reprint requests to the Department of Ophthalmology, University of California, Davis, Medical Center, 1603 Alhambra Blvd, Sacramento, CA 95816 (Dr Keltner).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Retinal Dysfunction in Cancer-Associated Retinopathy Is Improved by Ca2+ Antagonist Administration and Dark Adaptation
Ohguro et al.
IOVS 2001;42:2589-2595.
ABSTRACT | FULL TEXT  

Retinopathies Associated with Antiretinal Antibodies
Hooks et al.
CVI 2001;8:853-858.
FULL TEXT  

Antirecoverin Antibodies and Autoimmune Retinopathy
Adamus
Arch Ophthalmol 2000;118:1577-1578.
FULL TEXT  

Aberrant Expression of Photoreceptor-specific Calcium-binding Protein (Recoverin) in Cancer Cell Lines
Maeda et al.
Cancer Res. 2000;60:1914-1920.
ABSTRACT | FULL TEXT  

Human Melanoma-Associated Retinopathy (MAR) Antibodies Alter the Retinal ON-Response of the Monkey ERG In Vivo
Lei et al.
IOVS 2000;41:262-266.
ABSTRACT | FULL TEXT  

Cancer-Associated Retinopathy Induced by Both Anti-Recoverin and Anti-hsc70 Antibodies In Vivo
Ohguro et al.
IOVS 1999;40:3160-3167.
ABSTRACT | FULL TEXT  

Cancer-Associated Retinopathy
Goldstein et al.
Arch Ophthalmol 1999;117:1641-1645.
ABSTRACT | FULL TEXT  

Treatment of Paraneoplastic Visual Loss With Intravenous Immunoglobulin: Report of 3 Cases
Guy and Aptsiauri
Arch Ophthalmol 1999;117:471-477.
ABSTRACT | FULL TEXT  

Antibody Reactions With Retina and Cancer-Associated Antigens in 10 Patients With Cancer-Associated Retinopathy
Thirkill et al.
Arch Ophthalmol 1993;111:931-937.
ABSTRACT  

Intraperitoneal Cultivation of Small-cell Carcinoma Induces Expression of the Retinal Cancer-Associated Retinopathy Antigen
Thirkill et al.
Arch Ophthalmol 1993;111:974-978.
ABSTRACT